Entrectinib -- Anyone familiar? Oncologist suggested consideration downline due to rare ROS1 PRKG1-ROS1 fusion shown by Foundation One.

[Barbara345]

Hi all,

Foundation One results came back, liquid and solid studies. It showed ROS1 PRKG1-ROS1 fusion; MO didn't mention any other treatable variations. Apparently this variation happens in perhaps 1% of cancers. Oncologist said entrectinib was recently approved for ROS1 PRKG1-ROS1 fusion, for use if other treatment doesn't work. It looks likely that they'll try to keep him on Cabazitaxel right now, considering entrectinib if this fails.

INTERESTING POINT: According to cancer.gov, "This is the third cancer drug that has been approved for a “tissue agnostic” indication, meaning for tumors with a specific genetic feature rather than a certain type of tumor."

Is anyone familiar with this? I noticed no posts on this board so far.

Thanks!

Oh, I do plan to go through the rest of the report and look other genetic "finds," trials, etc.....